The best indicator for Gilead Sciences (GILD)
We backtested 20 indicators across daily, weekly and hourly charts on real Gilead Sciences (GILD) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Bollinger Mean-Reversion
On the daily chart, this is the strongest risk-adjusted edge we found for Gilead Sciences (GILD) over ~34.3 years — trailing buy-and-hold by 4.8% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Bollinger Mean-Reversion ✓ | Daily | 13.3% | 0.64 | -43.7% | 69.9% | 143 | -4.8% |
| 2 | Stochastic ✓ | Daily | 15.2% | 0.63 | -53.4% | 76.4% | 191 | -2.8% |
| 3 | Williams %R ✓ | Daily | 12.2% | 0.53 | -55.4% | 70.4% | 233 | -5.8% |
| 4 | Williams %R ✓ | Weekly | 11.4% | 0.53 | -46.8% | 71.7% | 53 | -6.2% |
| 5 | Holy Grail Confluence ✓ | Daily | 9.7% | 0.51 | -51.0% | 76.6% | 47 | -8.3% |
| 6 | Stochastic ✓ | Weekly | 9.6% | 0.49 | -46.8% | 68.6% | 35 | -8.0% |
| 7 | WaveTrend (8/6/4) ✓ | Weekly | 8.7% | 0.48 | -47.6% | 71.4% | 28 | -8.9% |
| 8 | WaveTrend (8/6/4) ✓ | Daily | 10.6% | 0.47 | -59.5% | 73.7% | 137 | -7.4% |
| 9 | CCI ✓ | Weekly | 8.4% | 0.46 | -46.0% | 72.7% | 33 | -9.2% |
| 10 | CCI ✓ | Daily | 9.1% | 0.44 | -53.4% | 69.8% | 162 | -9.0% |
| 11 | EMA 50/200 Cross ✓ | Daily | 9.5% | 0.43 | -78.1% | 34.6% | 26 | -8.5% |
| 12 | EMA 20/50 Cross ✓ | Weekly | 8.7% | 0.41 | -70.2% | 36.8% | 19 | -8.9% |
| 13 | Money Flow Index ✓ | Daily | 7.5% | 0.39 | -59.2% | 63.2% | 38 | -10.5% |
| 14 | SMA 50/200 Cross ✓ | Daily | 7.2% | 0.37 | -75.4% | 56.7% | 30 | -10.8% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Gilead Sciences (GILD), Bollinger Mean-Reversion on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.